These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 37487077)

  • 1. Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodies.
    Lax BM; Palmeri JR; Lutz EA; Sheen A; Stinson JA; Duhamel L; Santollani L; Kennedy A; Rothschilds AM; Spranger S; Sansom DM; Wittrup KD
    Proc Natl Acad Sci U S A; 2023 Aug; 120(31):e2300895120. PubMed ID: 37487077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control.
    Sanseviero E; O'Brien EM; Karras JR; Shabaneh TB; Aksoy BA; Xu W; Zheng C; Yin X; Xu X; Karakousis GC; Amaravadi RK; Nam B; Turk MJ; Hammerbacher J; Rubinstein MP; Schuchter LM; Mitchell TC; Liu Q; Stone EL
    Cancer Immunol Res; 2019 Aug; 7(8):1371-1380. PubMed ID: 31239316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fc-independent functions of anti-CTLA-4 antibodies contribute to anti-tumor efficacy.
    Sato Y; Casson CN; Matsuda A; Kim JI; Shi JQ; Iwasaki S; Chen S; Modrell B; Chan C; Tavares D; Austen D; Ida K; Tayber O; Hein P; Comeau R; Lin Y; Shaw MH
    Cancer Immunol Immunother; 2022 Oct; 71(10):2421-2431. PubMed ID: 35237846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8
    Semmrich M; Marchand JB; Fend L; Rehn M; Remy C; Holmkvist P; Silvestre N; Svensson C; Kleinpeter P; Deforges J; Junghus F; Cleary KL; Bodén M; Mårtensson L; Foloppe J; Teige I; Quéméneur E; Frendéus B
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35058324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An anti-CTLA-4 heavy chain-only antibody with enhanced T
    Gan X; Shan Q; Li H; Janssens R; Shen Y; He Y; Chen F; van Haperen R; Drabek D; Li J; Zhang Y; Zhao J; Qin B; Jheng MJ; Chen V; Wang J; Rong Y; Grosveld F
    Proc Natl Acad Sci U S A; 2022 Aug; 119(32):e2200879119. PubMed ID: 35925889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials.
    Curtin JF; Candolfi M; Fakhouri TM; Liu C; Alden A; Edwards M; Lowenstein PR; Castro MG
    PLoS One; 2008 Apr; 3(4):e1983. PubMed ID: 18431473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment.
    Knorr DA; Blanchard L; Leidner RS; Jensen SM; Meng R; Jones A; Ballesteros-Merino C; Bell RB; Baez M; Marino A; Sprott D; Bifulco CB; Piening B; Dahan R; Osorio JC; Fox BA; Ravetch JV
    Cancer Immunol Res; 2024 Mar; 12(3):322-333. PubMed ID: 38147316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Neuropilin-1 Antagonist Exerts Antitumor Immunity by Inhibiting the Suppressive Function of Intratumoral Regulatory T Cells.
    Jung K; Kim JA; Kim YJ; Lee HW; Kim CH; Haam S; Kim YS
    Cancer Immunol Res; 2020 Jan; 8(1):46-56. PubMed ID: 31554638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3
    Sharma A; Subudhi SK; Blando J; Scutti J; Vence L; Wargo J; Allison JP; Ribas A; Sharma P
    Clin Cancer Res; 2019 Feb; 25(4):1233-1238. PubMed ID: 30054281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells.
    Tekguc M; Wing JB; Osaki M; Long J; Sakaguchi S
    Proc Natl Acad Sci U S A; 2021 Jul; 118(30):. PubMed ID: 34301886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical development of a novel CCR8/CTLA-4 bispecific antibody for cancer treatment by disrupting CTLA-4 signaling on CD8 T cells and specifically depleting tumor-resident Tregs.
    Guo C; Dai X; Du Y; Xiong X; Gui X
    Cancer Immunol Immunother; 2024 Aug; 73(10):210. PubMed ID: 39123089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade?
    Tang F; Du X; Liu M; Zheng P; Liu Y
    Cell Biosci; 2018; 8():30. PubMed ID: 29713453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual targeting of CTLA-4 and CD47 on T
    Zhang A; Ren Z; Tseng KF; Liu X; Li H; Lu C; Cai Y; Minna JD; Fu YX
    Sci Transl Med; 2021 Aug; 13(605):. PubMed ID: 34349035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody.
    Ha D; Tanaka A; Kibayashi T; Tanemura A; Sugiyama D; Wing JB; Lim EL; Teng KWW; Adeegbe D; Newell EW; Katayama I; Nishikawa H; Sakaguchi S
    Proc Natl Acad Sci U S A; 2019 Jan; 116(2):609-618. PubMed ID: 30587582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.
    Selby MJ; Engelhardt JJ; Quigley M; Henning KA; Chen T; Srinivasan M; Korman AJ
    Cancer Immunol Res; 2013 Jul; 1(1):32-42. PubMed ID: 24777248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic depletion of CCR8
    Van Damme H; Dombrecht B; Kiss M; Roose H; Allen E; Van Overmeire E; Kancheva D; Martens L; Murgaski A; Bardet PMR; Blancke G; Jans M; Bolli E; Martins MS; Elkrim Y; Dooley J; Boon L; Schwarze JK; Tacke F; Movahedi K; Vandamme N; Neyns B; Ocak S; Scheyltjens I; Vereecke L; Nana FA; Merchiers P; Laoui D; Van Ginderachter JA
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intratumoral stem-like CCR4+ regulatory T cells orchestrate the immunosuppressive microenvironment in HCC associated with hepatitis B.
    Gao Y; You M; Fu J; Tian M; Zhong X; Du C; Hong Z; Zhu Z; Liu J; Markowitz GJ; Wang FS; Yang P
    J Hepatol; 2022 Jan; 76(1):148-159. PubMed ID: 34689996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-1 or CTLA-4 blockade promotes CD86-driven Treg responses upon radiotherapy of lymphocyte-depleted cancer in mice.
    Frijlink E; Bosma DM; Busselaar J; Battaglia TW; Staal MD; Verbrugge I; Borst J
    J Clin Invest; 2024 Feb; 134(6):. PubMed ID: 38349740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulatory T Cell Depletion Using a CRISPR Fc-Optimized CD25 Antibody.
    van Elsas MJ; van der Schoot JMS; Bartels A; Steuten K; van Dalen D; Wijfjes Z; Figdor CG; van Hall T; van der Burg SH; Verdoes M; Scheeren FA
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transient Treg depletion enhances therapeutic anti-cancer vaccination.
    Fisher SA; Aston WJ; Chee J; Khong A; Cleaver AL; Solin JN; Ma S; Lesterhuis WJ; Dick I; Holt RA; Creaney J; Boon L; Robinson B; Lake RA
    Immun Inflamm Dis; 2017 Mar; 5(1):16-28. PubMed ID: 28250921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.